Hepatic Disease in HIV-Infected Patients

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/4/18 (What's New)

Summary

  • Rates of noncirrhotic portal hypertension have ranged from 1%[Maida 2006] to 8% of HIV-infected patients[Mallet 2007]
  • No single etiology or characteristic histologic finding has been identified to explain noncirrhotic portal hypertension in HIV-infected patients without HBV or HCV infection
  • FDA published an alert about the risk of noncirrhotic portal hypertension in patients taking didanosine and added new information to the prescription label[FDA 2010]

    Action required